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aBstraCt
Background
A patent foramen ovale (PFO) consists of a hole between 
the right and left atriums of the heart that did not close 
the way it should after birth. Twenty five percent of the 
population have a PFO, but this usually does not cause 
problems, because the opening is functionally closed 
by the difference in pressure between the heart and the 
chest.
Method
This study is a literature review about the clinical 
significance of PFO and its management in three clinical 
situations: cryptogenic strokes, migraine with aura and 
scuba divers who sustained a decompression sickness.  
results and conclusion
PFOs had been linked with various medical 
conditions such as strokes, migraine, and with certain 
types of decompression sickness (DCS). In general, this 
association is not very well established. Young patients 
who sustain a cardiovascular event without a known 
cause (cryptogenic stroke) have resulted in the tendency 
to screen these patents becoming the norm and more 
PFOs are being closed using standard methods and 
devices. The association of PFOs and migraine attacks is 
less clear. In the case of scuba divers the risk of suffering 
from a decompression accident is increased if one has a 
PFO. The management of these patients remains difficult. 
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intrODUCtiOn 
A PFO is a defect in the septum between the two 
atrial chambers of the heart. Specifically, the defect is an 
incomplete closure of the atrial septum that results in the 
creation of a flap or a valve-like opening in the atrial septal 
wall. A PFO is present in everyone before birth but seals 
shut in about 75 to 80 per cent of the population. The 
cause of a PFO is unknown. There are no known risk 
factors. PFOs have been found on autopsy in up to 35 
per cent of the healthy population (Laskowski, 2012). 
PFOs anD CryPtOGEniC strOKEs
Crytogenic strokes are those cerebrovascular 
accidents  in usually young patients where the cause 
remains unknown despite extensive diagnostic work 
up. This type of stroke amounts to forty percent of all 
strokes (Sacco, et al., 1989). The prevalence of a PFO 
is approximately doubled among cryptogenic stroke 
(CS) patients. Regardless of mechanism, nearly 30,000 
young patients each year have a cryptogenic stroke and 
a PFO. This has generally been attributed to paradoxical 
embolism, and many physicians recommend PFO closure 
to prevent recurrence (Kent and Thaler, 2010). Since 
1988, studies have shown that a PFO is significantly 
more frequent in young stroke patients (less than 55 
yrs)  than in matched control subjects, and paradoxical 
embolism has been suggested as the main mechanism of 
stroke in these patients (Rodriguez and Homma, 2003). 
Nonetheless, another  study on 68 patients aged less 
than 55 years concluded that paradoxical embolism is 
not the primary mechanism of stroke in patients with a 
patent foramen ovale (Ranoux, 1993). 
The association in older patients remains uncertain 
as only a few studies have included patients more than 
55 years old. Nonetheless, one study confirmed the 
association between the presence of a PFO and CS in 
both patients younger than 55 years of age and those 55 
years of age or older (Handke, 2007). 
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The question at present is whether we should screen 
patients for PFOs and what the managment should 
be when a PFO is discovered. Optimal management 
at present is still desirable. There are ongoing studies 
and trials to compare the effectiveness of percutaneous 
closure of the PFOs with medical therapy and to study 
the outcomes in the hope of issuing guidelines for 
the management of these patients. The Randomized 
Evaluation of Recurrent Stroke Comparing PFO Closure 
to Established Current Standard of Care Treatment was an 
industry-sponsored trail (Respect Trial, 2012). This trial, 
started in 2007, recruited 900 participants aged between 
18 and 60 years. The trial was concluded in August 2012. 
Patients who had a cryptogenic stroke within the last 
270 days and patients who have been diagnosed with a 
PFO were included. Those found to have a PFO had an 
intervention to close the defect using a Amplatzer PFO 
Occluder device and later tested to ensure a successful 
procedure by using transthoracic echocardiography (TTE) 
and bubble studies. These patients were compared with 
patients who were treated medically using aspirin alone, 
Coumadin alone, Clopidogrel alone, or Aspirin combined 
with Dipyridamole. For carefully selected patients with 
history of cryptogenic stroke and PFO, the Respect Trial 
provided evidence of benefit in stroke risk reduction from 
closure with the Amplatzer PFO Occluder over medical 
management alone. Stroke risk reduction was observed 
across the totality of analyses with rates ranging from 
46.6% - 72.7%. PFO closure with the Amplatzer PFO 
Occluder exposed patients to a very low risk of device- or 
procedure-related complications. RESPECT remains the 
best trial showing the benefits of PFO closure in reducing 
the incidence of associated stroke.
Another trail included the Evaluation of the STARFlex 
Septal Closure System in Patients with a Stroke or TIA 
due to the Possible Passage of Clot of Unknown Origin 
through a PFO (Closure 1). Preliminary results from this 
trial showed that alternative explanation unrelated to 
paradoxical embolism present in 80 per cent of patients 
with recurrent stroke or TIA and that percutaneous 
closure with STARFlex® plus medical therapy does not 
offer any significant benefit over medical therapy alone 
for the prevention of recurrent stroke or TIA in patients 
< aged 60 presenting with cryptogenic stroke or TIA 
and a PFO. The other trial was the PC (Percutaneous 
Closure-Trial: PFO and Cryptogenic Embolism (Khattab, 
et al., 2011). However, patients taking part in these trials 
were all 60 years or younger on enrollment. Further trials 
with older participants are needed in order to develop 
diagnostic and therapeutic guidelines. Another trial 
which can throw some light on this, is the ongoing trial 
by Kent and Thaler (2011) called the Risk of Paradoxical 
Embolism (RoPE) Study which is aimed to develop and 
test a set of predictive models that can identify those 
patients most likely to benefit from preventive treatments 
for PFO-related stroke recurrence, such as PFO closure. 
The study is still ongoing. A study by Akhondi, et al., 
(2010) which evaluated the relationship between the 
morphological and functional size of the PFO showed 
that PFO size or morphology should not be used as the 
only criteria to decide whether a PFO should be closed. 
PFOs anD MiGrainE 
An association between migraine with aura and PFO 
with shunting has been suggested (Tepper, Sheftfell & 
Bigal, 2007). An association of migraine with aura and 
Osler-Weber-Rendu disease has also been proposed, with 
the mechanism likely to be shunting though pulmonary 
arteriovenous malformations (Dalla Volta, et al., 2005). 
This study confirmed previous observations of a link 
between migraine with aura, cluster headaches and PFO. 
The study also suggested that such an association was 
independent to migraine clinical phenotype and was 
probably unrelated to the pathogenic mechanism of 
paradoxical embolism.
In a quantitative systematic review, a low to moderate 
level of evidence for the association between migraine 
(with or without aura) and PFO was found (Schwedt, 
Demaerschalk and Dodick, 2008).
Six studies of the effects of PFO closure on migraine 
showed an improvement but had a very low grade of 
evidence. The low-to-moderate grade of evidence from 
observational studies supported an apparent association 
between PFO and migraine. Although PFO closure 
seemed to affect migraine patterns favourably, the very 
low grade of available evidence to support this association 
precluded definitive conclusions. It has already been 
stated that prospective, controlled, clinical trials designed 
to evaluate the efficacy and safety of percutaneous device 
closure of PFO for migraine prevention were needed 
(Schwedt and Dodick, 2006).  
On the other hand, in a multi-ethnic, elderly, 
population-based cohort, it was found that the presence 
of a PFO was not associated with self-reported migraine. 
This study also showed that the causal relationship 
between PFO and migraine remained uncertain, and 
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the role of PFO closure among unselected patients with 
migraine remains questionable (Rundle, et al., 2008). 
On the other hand, a case control study showed that 
compared with medical treatment, closure of PFO brings 
about a significant overall improvement in migraine. 
This seems to occur irrespective of migraine type and of 
previous cerebrovascular disease (Anzola, et al., 2006). 
In addition to the overall improvement in migraine with 
aura, the occurrence of aura is dramatically reduced. In 
a study of 121 patients with migraine it was again found 
that there is a possible association of migraine with aura 
and PFO. But it seems that PFO does not influence the 
type of aura and frequency of attacks of migraine as well 
as it is not associated with familial occurrence of migraine 
(Domitrz and Mieszkowski, 2008).
PFOs anD MyOCarDiaL inFarCtiOn
PFOs have been implicated as being also a risk factor 
not only for stroke and migraine but also for myocardial 
infarction and other ischemic vascular events (Diener, 
Tobias and Dodick, 2007). Although we have this 
evidence, explanation for these associations remains 
desirable.
PFOs anD sCUBa DiVErs
Right-to-left shunts are also associated with certain 
forms of neurological decompression sickness (DCS) 
in SCUBA (self-contained underwater breathing 
apparatus) divers (Wilmshurst and Bryson, 2000). 
The neurological decompression illness can occur after 
normal dives according to decompression tables, as a 
result of paradoxical gas embolism. A small number of 
observations suggested that cutaneous decompression 
illness was also associated with a right-to-left shunt, 
although embolic aetiology of a diffuse rash was more 
difficult to explain (Wilmshurst, et al., 2001). Cutaneous 
decompression illness has two possible mechanisms. 
The first mechanism was associated with a large right-
to-left shunt, when it seemed that  paradoxical gas 
embolism from peripheral bubble emboli invaded tissues 
supersaturated with nitrogen. Secondly, cutaneous 
decompression illness could occur in individuals without 
a shunt. In these subjects, the mechanism might be 
bubble emboli passing through an ‘overloaded’ lung filter 
or autochthonous bubble formation (Wilmshurst, et al., 
2001).  PFOs that caused DCS were 8mm in diameter or 
more (the larger the area the greater the shunting and the 
greater the chance of a DCS). PFOs which are smaller in 
diameter are found in about 15 per cent of the general 
population, but in only about 3 per cent of these did 
shunt related DCS occur. Also the diameter of a PFO is 
only partly correlated with propensity to shunt, because 
additional factors, such as mobility and stiffness of the 
flap covering the PFO, right atrial pressure that varies with 
activities, and atrial flow characteristics affect shunting 
(Wilmshurst, 2012). Today, we know that virtually most 
types of bends affecting the skin are related to right to left 
shunts across a PFO.  We have more data about PFOs 
than many other fitness-to-dive issues, so if anyone has 
a cutaneous decompression illness, this is more likely to 
be PFO related, and therefore, the diver involved merits 
to be screened for a PFO (Wilmshurst, 2012). 
The United Kingdom Sport Diving Medical Committee 
(UKSDMC) meeting about screening agreed that it was 
not reasonable to screen all, but that the potential groups 
where screening may be appropriate would be those 
with a previous DCS and those with migraine with aura 
(UKSDMC, 2001). 
The rationale is that a diver who has a documented 
PFO, theoretically, has an increased risk of DCS. He has to 
make a more reasonable risk assessment if he wants to do 
high decompression stress diving.  Having the test does 
not commit him to a closure procedure.  He may simply 
modify his diving. If a diver had a history of migraine with 
aura, and suffered even once decompression illness, he 
should be definitely screened for a PFO. Current evidence 
on the efficacy of percutaneous closure of PFO for the 
secondary prevention of recurrent paradoxical embolism 
in divers is inadequate in quality and quantity, and the 
evidence on safety shows that there is a possibility of 
serious complications. Therefore, this procedure should 
only be used with special arrangements for clinical 
governance, consent and audit or reseach (NICE, 2010).
Screening tests for PFOs and the subsequent 
closure procedure can be a costly business, so 
the decision to go ahead is not a light one to 
take. The patients needing to know  whether 
they have a PFO need to be counselled about why they 
want to know and what they will do with the information 
and disadvantages of knowing (such as adverse effects on 
insurance premiums). This strategy actually takes longer 
than it takes to close a PFO. So essentially, at present, 
the criteria for doing a contrast echo include divers with 
migraine with aura and no history of DCS and divers 
who are about to go to do some high risk diving in a 
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place remote from recompression facilities. Otherwise, 
the only candidates for screening for PFO are divers who 
have had a DCS and intend to persist with diving, young 
people who sustained some form of cryptogenic strokes 
and  those patients awaiting posterior fossa neurosurgery 
Wilmshurst, 2012). 
COnCLUsiOn
For carefully selected patients with history of 
cryptogenic stroke and PFO, the Respect Trial provides 
evidence of benefit in stroke risk reduction by closure 
with the Amplazter PFO Occluder over medical 
management alone. The PFO size or morphology should 
not be the only criteria to decide whether a PFO should 
be closed in case of paradoxical embolism. The link 
between PFOs and DCS has been amply demonstrated. 
The closure of the PFO, when it was done well, resulted 
in a reduction in the risk of a DCS.  The occurrence of 
a PFO in divers who had a DCS may be of consequence 
and its closure may be contemplated. The association 
between migraine and PFOs is not well established. No 
sound evidence exits so far that closure of PFOs will 
reduce the incidence of migraine. 
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